March 21, 2017 Clinical Research/Diagn. M&A, Partnerships Product Launch

SCIEX and the Children’s Medical Research Institute Announce Opening of ProCan to Advance Precision Medicine

SCIEX industrialised proteomics solutions, using microflow SWATH® Acquisition, will accelerate cancer research March 21, 2017 Framingham, MA U.S.A. and Sydney, Australia — SCIEX, a global leader in life science analytical technologies, has announced that Children’s Medical Research Institute (CMRI) has opened ProCan™, the Australian Cancer Research Foundation International Centre for the Proteome of Human Cancer.... Read more

February 8, 2017 Life Science Tools M&A, Partnerships

Integrated DNA Technologies acquires oligo manufacturing business of GeneWorks (Australia)

IDT expands its capacity for direct sales of genomic products in Asia-Pacific region SKOKIE, IL (February 8, 2017) – Integrated DNA Technologies (IDT), through its Singapore subsidiary, today completed the acquisition of the oligonucleotide manufacturing business of GeneWorks Pty Ltd. (GeneWorks) in Australia. This acquisition sees IDT expand its reach in the Asia-Pacific region, following... Read more

January 30, 2017 Bio/Pharma/CRO Clinical Research/Diagn.

Announcement on submission of the Clinical Trial Plan Notification for phase II clinical trial of Oncolytic virus HF10 in Japan

2017 2017/01/30 Announcement on submission of the Clinical Trial Plan Notification for phase II clinical trial of Oncolytic virus HF10 in Japan Kusatsu/Shiga, Japan — January 30, 2017 — Takara Bio Inc. (Takara Bio), today announced that the Clinical Trial Notification was submitted to PMDA (Pharmaceuticals and Medical Devices Agency; Japanese regulatory agency) to conduct... Read more

January 24, 2017 Bio/Pharma/CRO Clinical Research/Diagn.

Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of NY-ESO-1・siTCR gene therapy in Japan

2017 2017/01/24 Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of NY-ESO-1・siTCR gene therapy in Japan Kusatsu/Shiga, Japan — January 24, 2017 — Takara Bio Inc. (Takara Bio), today announced that it has submitted the Clinical Trial Notification for regenerative medicines to PMDA (Pharmaceuticals and Medical Devices Agency), Japanese... Read more

January 11, 2017 Bio/Pharma/CRO Clinical Research/Diagn.

Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of CAR gene therapy in Japan

2017 2017/01/11 Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of CAR gene therapy in Japan Kusatsu/Shiga, Japan — January 11, 2017 —Takara Bio Inc. (Takara Bio), today announced that it has submitted the Clinical Trial Notification for regenerative medicines to PMDA (Pharmaceuticals and Medical Devices Agency), Japanese regulatory... Read more

January 3, 2017 Licensing, IP, and Legal

GE Healthcare to commercialize Rapiscan® outside the US, Canada & Mexico for increased access to heart exams

CHALFONT ST. GILES, UK – 3 January, 2017 – GE Healthcare’s Life Sciences business announced today that it has acquired Rapidscan Pharma Solutions Inc., which has the exclusive rights to produce and sell the pharmacological stress agent Rapiscan® (regadenoson) in territories outside the USA, Canada and Mexico. GE Healthcare’s strong industry presence and existing customer and... Read more

May 9, 2016 Bio/Pharma/CRO

JHL Biotech Opens Innovative Biosimilars Manufacturing Facility in China

CHALFONT ST. GILES, UK and WUHAN, CHINA – 10 May 2016 –JHL Biotech (JHL), a biopharmaceutical company, opened the world’s first KUBio™ biopharmaceutical manufacturing facility with single-use bioprocessing technology at a ribbon-cutting ceremony in Wuhan, China today. JHL will use the KUBio manufacturing solution delivered by GE Healthcare to manufacture biosimilars(1) and monoclonal antibodies (mAbs)... Read more

February 29, 2016 Bio/Pharma/CRO M&A, Partnerships

JHL Biotech Announces Mechanical Completion of its Wuhan Biopharmaceutical Manufacturing Facility

WUHAN, China and AMERSHAM, England, Feb. 25, 2016 /PRNewswire/ — JHL Biotech (TPEx: 6540) and GE Healthcare’s Life Sciences business (NYSE: GE) are proud to announce mechanical completion of JHL Biotech’s JHL-1 biopharmaceutical manufacturing facility in the Biolake area of Wuhan, China. The campus was built to be compliant with the highest international standards, and after site validation is completed in June... Read more